If you have been reading about metabolic research and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-01-12. Numbers and descriptions here follow the published literature rather than marketing material.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
| Property | Value | Notes |
|---|---|---|
| Primary research area | Obesity and metabolic regulation | Studied in cell, animal, and human models |
| Highest reported trial phase | Phase II | Public summaries describe mixed results |
| Common route in trials | Subcutaneous injection | Typical for peptide therapeutics |
| Regulatory example | 2013 Australian anti-doping review | Classification was debated at the time |
| Approval status | Not approved as a human medicine | Status can change by jurisdiction |
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
==== Specialty selection ==== Specialties differ in length of training, availability of residencies, and options. Specialist residency programs require participation for completion ranging from three years for family medicine to seven years for neurosurgery. This time does not include any fellowship that may be required to be completed after residency to further sub-specialize. In regard to options, specialty residency programs can range nationally from over 700 (family medicine) and over 580 (internal medicine) to 33 programs for integrated thoracic surgery and 28 programs for osteopathic neuromusculoskeletal medicine. Residents choose the teaching hospital where they want to perform their residency based upon many factors, including the medical specialties offered by the hospital and reputation and credentials of the hospital. The following table shows medical specialties and the residency training times for medical specialties, as reported by the American Medical Association in 2021.
Risk factors for opioid overdose include opioid dependence, injecting opioids, using high doses of opioids, and use together with alcohol, benzodiazepines, or cocaine. The risk is particularly high following detoxification. Dependence on prescription opioids can occur from their use to treat chronic pain. In young children, an overdose is usually due to opioids that are intended for their parents, older siblings, or grandparents. In mothers who take codeine during breastfeeding, opioid overdoses have occurred in their baby. Codeine is, therefore, not recommended for those who are breastfeeding.
== Side effects == Side effects of fentanyl analogs are similar to those of fentanyl itself, which include itching, nausea and potentially serious respiratory depression, which can be life-threatening. Fentanyl analogs have killed hundreds of people throughout Europe and the former Soviet republics since the most recent resurgence in use began in Estonia in the early 2000s, and novel derivatives continue to appear. As acrylamide derivatives are often used in drug discovery to make covalent inhibitors which will bind irreversibly to its target, acrylfentanyl is claimed to be naloxone resistant. However, acute intoxications with acrylfentanyl on mice treated by naloxone (2 mg/kg) have shown that acrylfentanyl could be displaced from the opioid receptor. Acrylfentanyl has been linked to 20 deaths in Sweden as well as two deaths in Denmark in summer 2016.
=== Structural proteomics === A third area of Borchers' research is structural proteomics, which combines protein chemistry methods—such as cross-linking, hydrogen–deuterium exchange and photoaffinity labelling—with mass spectrometry and molecular modelling to study protein structure and interactions. This work includes the study of protein folding and misfolding associated with diseases such as Parkinson's disease and cystic fibrosis. In 2011, Borchers co-founded the Symposium on Structural Proteomics with Evgeniy Petrotchenko, and the two have co-organized the international meeting annually since.
== Pathology == The microscopic histopathology of hematoxylin and eosin stained FBS tumors varies. Lower-grade MFS tissues consist of scattered large, variability-sized and spindle-shaped-to-variably-shaped tumor cells with darkly stained nuclei. Overall, lower-grade tumors contain relatively few cells within a distinctive myxoid (i.e. more blue or purple compared to normal connective tissue because of excessive uptake of the hematoxylin stain) connective tissue background that contains curvilinear, thin-walled blood vessels. Higher grade FBS tumors consist of relatively large sheets of these spindle-shaped/vatiably-shaped cells in a similar myxoid background containing thin-walled curvilinear blood vessels. Pseudo-lipoblasts (i.e. multivacuolated cells resembling lipoblasts but having vacuoles filled with mucin rather than lipids) are apparent in both lower grade and higher grade tumors. Epithelioid FBS tumors are highly cellular lesions consisting of diffuse proliferations of extremely large, polygonal-shaped epithelioid cells set in a myxoid connective tissue background similar to that seen in the other types of FBS. Epithelioid myxofibrosarcomas appear to behave more aggressively than myxofibrosarcomas dominated by spindle-shaped/variably-shaped cells. While the cells in most types of tumors express specific marker proteins that help in diagnosing them, the tumor cells in FBS and its epithelioid variant have not yet been found to express marker proteins that are sufficiently specific to support either diagnosis.
Sources: en.wikipedia.org
==== Reaction hosts with size selectivity ==== MOFs might prove useful for both photochemical and polymerization reactions due to the tuneability of the size and shape of their pores. A 3D MOF {[Co(bpdc)3(bpy)] • 4dmf • H2O} (bpdc: biphenyldicarboxylate, bpy: 4,4′-bipyridine) was synthesized by Li and coworkers. Using this MOF photochemistry of o-methyl dibenzyl ketone (o-MeDBK) was extensively studied. This molecule was found to have a variety of photochemical reaction properties including the production of cyclopentanol. MOFs have been used to study polymerization in the confined space of MOF channels. Polymerization reactions in confined space might have different properties than polymerization in open space. Styrene, divinylbenzene, substituted acetylenes, methyl methacrylate, and vinyl acetate have all been studied by Kitagawa and coworkers as possible activated monomers for radical polymerization. Due to the different linker size the MOF channel size could be tunable on the order of roughly 25 and 100 Å2. The channels were shown to stabilize propagating radicals and suppress termination reactions when used as radical polymerization sites.
== Occurrence and use == Even though D-amino acids are minimal constituents of living organisms, they occur in a broad range of natural environments such as soils, rivers, lakes, marine systems, snow and ice, aerosols and precipitation. They are produced by several marine microbes, which attain important roles in the carbon and energy cycles in the ocean, and contribute as a carbon source to the oceanic carbon reservoir. D-Amino acid residues occur in cone snails and the venom of the male platypus. They are also abundant components of the peptidoglycan cell walls of bacteria, and D-serine may act as a neurotransmitter in the brain. D-Amino acids are used in racemic crystallography to create centrosymmetric crystals, which, depending on the protein, may allow for easier and more robust protein structure determination. Gramicidin is a polypeptide made up from mixture of D- and L-amino acids. Other compounds containing D-amino acids are tyrocidine and valinomycin. These compounds disrupt bacterial cell walls, particularly in gram-positive bacteria. As of 2011, only 837 D-amino acids were found in the Swiss-Prot database out of a total of 187 million amino acids analysed. Fluorescently labeled D-amino acids, namely FDAAs, have been used for in situ labeling of bacterial peptidoglycan in both gram-positive and gram-negative species.
A strain field associated with a displacement is defined, at any point, by the change in length of the tangent vectors representing the speeds of arbitrarily parametrized curves passing through that point. A basic geometric result, due to Fréchet, von Neumann and Jordan, states that, if the lengths of the tangent vectors fulfil the axioms of a norm and the parallelogram law, then the length of a vector is the square root of the value of the quadratic form associated, by the polarization formula, with a positive definite bilinear form called the metric tensor.
Respondents in the 2021 Canadian census self-reported over 450 "ethnic or cultural origins". The major panethnic groups chosen were: European (52.5%), North American (22.9%), Asian (19.3%), North American Indigenous (6.1%), African (3.8%), Latin, Central and South American (2.5%), Caribbean (2.1%), Oceanian (0.3%), and other (6%). Over 60 percent of Canadians reported a single origin, and 36 percent reported having multiple ethnic origins, thus the overall total is greater than 100 percent.
Sources: en.wikipedia.org
A deuterated drug is a small molecule medicinal product in which one or more of the hydrogen atoms in the drug molecule have been replaced by deuterium. Because of the kinetic isotope effect, deuterium-containing drugs may have significantly lower rates of metabolism, and hence a longer half-life. In 2017, deutetrabenazine became the first deuterated drug to receive FDA approval.
== Chemical properties == Bismuth subcitrate potassium is a salt of bismuth (Bi3+), potassium (K+) and citrate (C6H4O4−7) in a molar ratio of about 1:5:2, with 3 moles of water. It contains about 25.6% (mass percent) bismuth, which is the active moiety, and 22.9% potassium. Other sources give somewhat different ratios of the constituents.
If this is the case, similarity in lifetimes of intermediate daughters becomes a meaningless argument, as different isomers of the same nuclide can have different half-lives: for example, the ground state of 180Ta has a half-life of hours, but an excited state 180mTa has never been observed to decay. This study found reason to doubt and criticise the IUPAC approval of the discoveries of elements 115 and 117, but the data from Riken for element 113 was found to be congruent, and the data from the JINR team for elements 115 and 113 to probably be so, thus endorsing the IUPAC approval of the discovery of element 113. Two members of the JINR team published a journal article rebutting these criticisms against the congruence of their data on elements 113, 115, and 117 in June 2017.
==== Japan ==== Taco Bell once operated shops in Tokyo and Nagoya in the 1980s but withdrew several years later. Since then, there were shops only at United States Forces Japan bases. In 2015, Taco Bell returned to the Japanese market with a new shop in the downtown area of Shibuya, Tokyo. It had "Taco rice" and "Shrimp and avocado burrito" on its original menu.
== Human importance == In pisciculture and fishkeeping, the slime coat is important to the health of fish, particularly during transport which can cause damage to it. High ammonia levels in the water can also cause damage to the slime coat. The antimicrobial properties of fish slime have been studied as an alternative to antibiotic drugs to address antibiotic resistance.
Sources: en.wikipedia.org
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.
It became prominent during a 2013 Australian sports investigation that examined whether it was a prohibited growth-hormone-related substance. Subsequent interpretations and list updates have varied, so current rules should be checked directly.
Published summaries generally report limited or inconsistent weight-loss effects, and complete trial data are not widely available. The studies were not sufficient to establish it as an effective obesity treatment.
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.